Top

Published in:

07-10-2023 | Myasthenia Gravis | Letter to the Editors

Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report

Authors: Zhouao Zhang, Zhouyi Wang, Xue Du, Xiaoyu Huang, Yong Zhang

Excerpt

Dir Sirs, …

Chen J, Tian D-C, Zhang C, Li Z, Zhai Y et al (2020) Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health West Pac 5:100063. https://doi.org/10.1016/j.lanwpc.2020.100063CrossRefPubMedPubMedCentral

Damato V, Spagni G, Monte G, Woodhall M, Jacobson L et al (2022) Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2022-329284CrossRefPubMed

Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM et al (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30. https://doi.org/10.1038/s41572-019-0079-yCrossRefPubMed

Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1756285617749134. https://doi.org/10.1177/1756285617749134CrossRefPubMedPubMedCentral

Gomez-Figueroa E, Garcia-Trejo S, Bazan-Rodriguez L, Cervantes-Uribe R, Chac-Lezama G et al (2020) Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis. J Neurol 267:674–678. https://doi.org/10.1007/s00415-019-09622-4CrossRefPubMed

Fan Y, Gao D, Zhang Z (2022) Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. Drugs Today (Barc) 58:23–32. https://doi.org/10.1358/dot.2022.58.1.3352743CrossRefPubMed

Sobieszczuk E, Szczudlik P, Kubiszewska J, Szyluk B, Lipowska M et al (2021) Lower BAFF levels in myasthenic patients treated with glucocorticoids. Arch Immunol Ther Exp (Warsz) 69:22. https://doi.org/10.1007/s00005-021-00626-5CrossRefPubMed

Shi F, Xue R, Zhou X, Shen P, Wang S et al (2021) Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43:666–673. https://doi.org/10.1080/08923973.2021.1973493CrossRefPubMed

Ma X, Fu X, Cui B, Lin H (2022) Telitacicept for recalcitrant cutaneous manifestations of systemic lupus erythematosus: a case report and review of the literature. Tohoku J Exp Med 258:219–223. https://doi.org/10.1620/tjem.2022.J074CrossRefPubMed

10.

Lv J, Liu L, Hao C, Li G, Fu P et al (2023) Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep 8:499–506. https://doi.org/10.1016/j.ekir.2022.12.014CrossRefPubMed

11.

Ding J, Jiang X, Cai Y, Pan S, Deng Y et al (2022) Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: a single-center, single-arm, open-label study. CNS Neurosci Ther 28:1613–1623. https://doi.org/10.1111/cns.13904CrossRefPubMedPubMedCentral

12.

Sun F, Wu H, Wang Z, Wu T, Wu X et al (2023) Effectiveness and safety of belimumab in Chinese lupus patients: a multicenter real-world observational study. Biomedicines. https://doi.org/10.3390/biomedicines11030962CrossRefPubMedPubMedCentral

13.

Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ et al (2018) Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology 90:e1425–e1434. https://doi.org/10.1212/WNL.0000000000005323CrossRefPubMedPubMedCentral

14.

Jourdan M, Cren M, Robert N, Bolloré K, Fest T et al (2014) IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia 28:1647–1656. https://doi.org/10.1038/leu.2014.61CrossRefPubMed

15.

Chen R, Fu R, Lin Z, Huang C, Huang W (2023) The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus. https://doi.org/10.1177/09612033221141253CrossRefPubMedPubMedCentral

Title: Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report
Authors: Zhouao Zhang
Zhouyi Wang
Xue Du
Xiaoyu Huang
Yong Zhang
Publication date: 07-10-2023
Publisher: Springer Berlin Heidelberg
Keywords: Myasthenia Gravis
Neuromyelitis Optica Spectrum Disease
Tacrolimus
Published in: Journal of Neurology / Issue 1/2024
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12036-y